Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy

被引:814
|
作者
Liao, Wei [1 ,2 ]
Lin, Jian-Xin [1 ,2 ]
Leonard, Warren J. [1 ,2 ]
机构
[1] NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA
[2] NHLBI, Ctr Immunol, NIH, Bethesda, MD 20892 USA
关键词
REGULATORY T-CELLS; RECEPTOR-ALPHA-CHAIN; SEVERE COMBINED IMMUNODEFICIENCY; GAMMA-CHAIN; BETA-CHAIN; IL-2; RECEPTOR; GENE-EXPRESSION; MONOCLONAL-ANTIBODY; GROWTH-FACTOR; IFN-GAMMA;
D O I
10.1016/j.immuni.2013.01.004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Interleukin-2 (IL-2) is a pleiotropic cytokine produced after antigen activation that plays pivotal roles in the immune response. Discovered as a T cell growth factor, IL-2 additionally promotes CD8(+) T cell and natural killer cell cytolytic activity and modulates T cell differentiation programs in response to antigen, promoting naive CD4(+) T cell differentiation into T helper 1 (Th1) and T helper 2 (Th2) cells while inhibiting T helper 17 (Th17) and T follicular helper (Tfh) cell differentiation. Moreover, IL-2 is essential for the development and maintenance of T regulatory cells and for activation-induced cell death, thereby mediating tolerance and limiting inappropriate immune reactions. In this review, we focus on the molecular mechanisms and complex cellular actions of IL-2, its cooperative and opposing effects with other cytokines, and how both promoting and blocking the actions of IL-2 are being utilized in clinical medicine.
引用
收藏
页码:13 / 25
页数:13
相关论文
共 50 条
  • [31] Interleukin-2 as anticancer immunotherapy in the age of checkpoint inhibition
    Garbe, Claus
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S313 - S314
  • [32] Liposomal delivery of interleukin-2 in locoregional anticancer immunotherapy
    Storm, G
    Koppenhagen, FJ
    Steerenberg, PA
    denOtter, W
    Crommelin, DJA
    23RD INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE OF BIOACTIVE MATERIALS, 1996 PROCEEDINGS, 1996, : 95 - 96
  • [33] Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer
    Rosenberg, SA
    CANCER JOURNAL, 2000, 6 : S2 - S7
  • [34] ADOPTIVE IMMUNOTHERAPY OF CANCER WITH ACTIVATED LYMPHOCYTES AND INTERLEUKIN-2
    KRADIN, RL
    KURNICK, JT
    PATHOLOGY AND IMMUNOPATHOLOGY RESEARCH, 1986, 5 (3-5): : 193 - 202
  • [35] Immunotherapy with interleukin-2: A study based on mathematical modeling
    Banerjee, Sandip
    INTERNATIONAL JOURNAL OF APPLIED MATHEMATICS AND COMPUTER SCIENCE, 2008, 18 (03) : 389 - 398
  • [36] ENHANCEMENT OF INTERLEUKIN-2 IMMUNOTHERAPY WITH L-ARGININE
    LIEBERMAN, MD
    NISHIOKA, K
    REDMOND, HP
    DALY, JM
    ANNALS OF SURGERY, 1992, 215 (02) : 157 - 165
  • [37] MULTICHAIN INTERLEUKIN-2 RECEPTOR - A TARGET FOR IMMUNOTHERAPY IN LYMPHOMA
    WALDMANN, TA
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (12): : 914 - 923
  • [38] NEW APPROACHES TO THE IMMUNOTHERAPY OF CANCER USING INTERLEUKIN-2
    ROSENBERG, SA
    LOTZE, MT
    MULE, JJ
    ANNALS OF INTERNAL MEDICINE, 1988, 108 (06) : 853 - 864
  • [39] Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy
    Wagner, Samuel C.
    Markosian, Boris
    Ajili, Naseem
    Dolan, Brandon R.
    Kim, Andy J.
    Alexandrescu, Doru T.
    Dasanu, Constantin A.
    Minev, Boris
    Koropatnick, James
    Marincola, Francesco M.
    Riordan, Neil H.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
  • [40] Interleukin-2 immunotherapy in auto-immune disorders
    Saadoun, D.
    Cacoub, P.
    REVUE DE MEDECINE INTERNE, 2013, 34 (03): : 133 - 135